-
Dec 30, 2024 | 
onlinelibrary.wiley.com | Xin Lan |Xin Zhong |Xiang Ding
Conflicts of Interest The authors declare no conflicts of interest. References 1, , , , and , “Phytochemicals Accumulation in Sanhua Plum (Prunus salicina L.) During Fruit Development and Their Potential use as Antioxidants,” Journal of Agricultural and Food Chemistry 67 (2019): 2459–2466. 2, , , , and , “Changes in the Primary Metabolites of ‘Fengtang’ Plums During Storage Detected by Widely Targeted Metabolomics,” Foods 11 (2022): 2830.
-
Oct 10, 2024 | 
science.org | Dimitri Fabrèges |Stephanie Hampton |Xin Lan |Tian Mi
Editor’s summaryT cell immunotherapies have been successful in treating some intractable cancers, but there are limitations caused by the inability of T cells to persist after prolonged stimulation. Kang et al. undertook a reverse-translation approach to investigate the molecular mechanisms regulating the durability of T cell responsiveness to checkpoint blockade immunotherapy (see the Perspective by Tsui and Kallies).
-
Sep 1, 2023 | 
science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Nisha Saif
Editors' ChoiceFOCIS HIGHLIGHTS It is estimated that at least 1 in 5 people infected with COVID-19 are asymptomatic. Despite the central role of human leukocyte antigen (HLA) variation in susceptibility to viral infection, relatively little is understood about its role in conferring protection against symptomatic COVID-19 disease. To shed light on this important question, Augusto et al.
-
Sep 1, 2023 | 
science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Asha Pillai
Editors' ChoiceFOCIS HIGHLIGHTS Immunotherapy harnessing tumor-infiltrating lymphocytes (TILs) is advancing cures for patients with otherwise-intractable solid tumors. Antibody-targeted endogenous CD8+ T cells and ex vivo engineered autologous chimeric antigen receptor T (CAR-T) or tumor specific antigen (TSA)–specific CD8+ T cells (TCR-T) are potent immunotherapies. However, immune escape when tumors downregulate class I or TSA expression is a key challenge to durable responses.
-
Sep 1, 2023 | 
science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Elena Mandrou
Published In Science ImmunologyVolume 8 | Issue 87September 2023Article versionsPermissionsRequest permissions for this article. AcknowledgmentsFunding: This work was funded by core grant A24450 from Cancer Research UK, Programme Grant MR/X000702/1 from the Medical Research Council (MRC), and Wellcome Investigator grant 221786/Z/20/Z to R.I.Author contributions: H.D., E.M., and R.I. wrote the manuscript. Competing interests: The authors declare that they have no competing interests.
-
Sep 1, 2023 | 
science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Caitlin C. Zebley
Published In Science ImmunologyVolume 8 | Issue 87September 2023Article versionsSubmission historyReceived: 20 December 2022Accepted: 9 August 2023PermissionsRequest permissions for this article. AcknowledgmentsWe thank members of Youngblood and Zebley laboratories for constructive feedback and editing. We apologize for any related studies not cited in this review due to the reference limit.
-
Sep 1, 2023 | 
sciencemag.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Caitlin C. Zebley
Published In Science ImmunologyVolume 8 | Issue 87September 2023Article versionsSubmission historyReceived: 20 December 2022Accepted: 9 August 2023PermissionsRequest permissions for this article. AcknowledgmentsWe thank members of Youngblood and Zebley laboratories for constructive feedback and editing. We apologize for any related studies not cited in this review due to the reference limit.
-
Sep 1, 2023 | 
sciencemag.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Asha Pillai
Editors' ChoiceFOCIS HIGHLIGHTSImmunotherapy harnessing tumor-infiltrating lymphocytes (TILs) is advancing cures for patients with otherwise-intractable solid tumors. Antibody-targeted endogenous CD8+ T cells and ex vivo engineered autologous chimeric antigen receptor T (CAR-T) or tumor specific antigen (TSA)–specific CD8+ T cells (TCR-T) are potent immunotherapies. However, immune escape when tumors downregulate class I or TSA expression is a key challenge to durable responses.
-
Sep 1, 2023 | 
sciencemag.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Elena Mandrou
Published In Science ImmunologyVolume 8 | Issue 87September 2023Article versionsPermissionsRequest permissions for this article. AcknowledgmentsFunding: This work was funded by core grant A24450 from Cancer Research UK, Programme Grant MR/X000702/1 from the Medical Research Council (MRC), and Wellcome Investigator grant 221786/Z/20/Z to R.I.Author contributions: H.D., E.M., and R.I. wrote the manuscript. Competing interests: The authors declare that they have no competing interests.
-
Sep 1, 2023 | 
sciencemag.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Mehmet Can Uçar
Published In Science ImmunologyVolume 8 | Issue 87September 2023Article versionsSubmission historyReceived: 11 May 2022Accepted: 9 August 2023PermissionsRequest permissions for this article. AcknowledgmentsWe thank I. de Vries and the Scientific Service Units (Life Sciences, Bioimaging, Nanofabrication, Preclinical and Miba Machine Shop) of the Institute of Science and Technology Austria for excellent support, as well as all the rotation students assisting in the laboratory work (B. Zens, H.
